1. Home
  2. KPTI vs VGI Comparison

KPTI vs VGI Comparison

Compare KPTI & VGI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KPTI
  • VGI
  • Stock Information
  • Founded
  • KPTI 2008
  • VGI 2012
  • Country
  • KPTI United States
  • VGI United States
  • Employees
  • KPTI N/A
  • VGI N/A
  • Industry
  • KPTI Biotechnology: Pharmaceutical Preparations
  • VGI Investment Managers
  • Sector
  • KPTI Health Care
  • VGI Finance
  • Exchange
  • KPTI Nasdaq
  • VGI Nasdaq
  • Market Cap
  • KPTI 81.1M
  • VGI 89.5M
  • IPO Year
  • KPTI 2013
  • VGI N/A
  • Fundamental
  • Price
  • KPTI $0.62
  • VGI $7.80
  • Analyst Decision
  • KPTI Strong Buy
  • VGI
  • Analyst Count
  • KPTI 4
  • VGI 0
  • Target Price
  • KPTI $5.00
  • VGI N/A
  • AVG Volume (30 Days)
  • KPTI 768.4K
  • VGI 46.0K
  • Earning Date
  • KPTI 02-19-2025
  • VGI 01-01-0001
  • Dividend Yield
  • KPTI N/A
  • VGI 12.66%
  • EPS Growth
  • KPTI N/A
  • VGI N/A
  • EPS
  • KPTI N/A
  • VGI N/A
  • Revenue
  • KPTI $148,442,000.00
  • VGI N/A
  • Revenue This Year
  • KPTI $4.47
  • VGI N/A
  • Revenue Next Year
  • KPTI $7.35
  • VGI N/A
  • P/E Ratio
  • KPTI N/A
  • VGI N/A
  • Revenue Growth
  • KPTI 1.77
  • VGI N/A
  • 52 Week Low
  • KPTI $0.58
  • VGI $6.68
  • 52 Week High
  • KPTI $1.70
  • VGI $7.99
  • Technical
  • Relative Strength Index (RSI)
  • KPTI 43.29
  • VGI 50.91
  • Support Level
  • KPTI $0.58
  • VGI $7.70
  • Resistance Level
  • KPTI $0.67
  • VGI $7.94
  • Average True Range (ATR)
  • KPTI 0.05
  • VGI 0.07
  • MACD
  • KPTI -0.00
  • VGI 0.00
  • Stochastic Oscillator
  • KPTI 31.02
  • VGI 53.13

About KPTI Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.

About VGI Virtus Global Multi-Sector Income Fund of Beneficial Interest

Virtus Global Multi-Sector Inc is a United States-based diversified, closed-end management investment company. Its investment objective is to maximize current income while preserving capital. The Fund seeks to achieve its investment objectives by capitalizing on opportunities across undervalued areas of the global bond markets.

Share on Social Networks: